Author: Gonzalo Alvaro

ROVI announces its financial results for the first nine months of 2025, a period in which it took strategic steps forward to reinforce its global reach and accelerate its growth.

One of the most significant milestones was the acquisition of a manufacturing facility for injectable pharmaceuticals in Phoenix (USA) from Bristol Myers Squibb (BMS), which positions ROVI as a global industrial player with direct presence in the United States market. In addition, as part of the transaction, a Toll Manufacturing Agreement has been signed with BMS, which regulates the conditions for continuing with the manufacture of its products at this facility.

Likewise, ROVI has announced that it will collaborate with Roche in the manufacture of a new medicine, currently in the clinical development phase, from Roche’s metabolic and cardiovascular portfolio.

ROVI booked operating revenue of 525.1 million euros, representing a 7% decrease on the first nine months of 2024, due to the behaviour of the contract manufacturing business.

Notwithstanding, sales of the specialty pharmaceutical business rose 10% to 343.4 million euros in the first nine months of the year.

Risperidone ISM® maintained its positive evolution, reaching total sales of 41.0 million euros in the first nine months of the year. This represents a 102% increase on the first nine months of 2024.

Sales of the heparin franchise, which includes low-molecular-weight heparins and other heparins, increased 7% to 189.8 million euros due to the increase in orders from international partners. The main contributor to the division’s growth was the enoxaparin biosimilar, sales of which rose 11% to 112.8 million euros in the first nine months of 2025 as a result of an increase in orders from partners during the period.

In addition, the contract manufacturing business (CDMO) booked sales of 181.7 million euros.

In the first nine months of 2025, the gross margin increased by 3.5 percentage points compared to the same period of 2024, reaching 67.1%.

Likewise, in the first nine months of 2025, EBITDA decreased 11% to 149.5 million euros.

Net profit was 97.7 million euros.

For 2025, ROVI expects operating revenue to decrease by a mid-single-digit percentage.

For 2026, ROVI expects its operating revenue to increase by between a high single-digit and low double-digit percentage compared to 2025.

This estimate is based on a number of factors whose evolution is difficult to predict, such as:

– Limited visibility of the evolution of the demand and production associated with the 2026 vaccination campaign,

– The potential revenue from the manufacturing agreement signed with Bristol Myers Squibb (still in the process of signature) as part of the transaction announced on 29 September 2025, and

– Revenues derived from other agreements related to contract manufacturing activities.

This Wednesday, Laboratorios Farmacéuticos Rovi, S.A. held its Ordinary General Shareholders’ Meeting, at which all the items on the agenda were approved, including the annual accounts for 2024 and the shareholder remuneration via dividend. Specifically, the Meeting, which reached a quorum on the first call, approved the distribution of a dividend of 0.9351 euros per share entitled to receive it, equivalent to a maximum of 47,910,561.05 euros, charged to the 2024 profit, representing a pay-out of 35% of ROVI’s consolidated net profit.

The 2025 General Shareholders’ Meeting was attended by 397 shareholders, both present and represented, holding a total of 44,104,081 shares, accounting for 86.081% of the Company’s share capital. The strong support received at the Meeting reflects the shareholders’ confidence in the current management team and the Company’s long-term growth strategy, with special focus on internationalisation, driving the contract manufacturing business (CDMO) forward and promoting innovation and the development of own products using the ISM® technology, such as Okedi® (Risperidone ISM®).

Mr Juan López-Belmonte Encina said: “2024 was a key year of transition in laying the foundations for our future. We focused on strengthening our capacity in the contract manufacturing area to address the imbalance between the growing demand and the limited supply of production capacities for injectables. The expansion of our production capacities places us in a favourable position to meet global market needs. Furthermore, Risperidone ISM® showed efficacy in treating schizophrenia with positive results that are reflected in an improvement in the patients’ quality of life. We are continuing to invest in research and development, taking advantage of the capabilities of our ISM® technology to provide innovative solutions that drive the well-being of society forward and help medicine to advance.”

Churriana de la Vega hosted the 9th edition of the Churriana Integra Race, a benchmark event in the field of adapted sports in the province of Granada. Of course, Team ROVI Granada could not miss the competition, organised by the Granada Integra Foundation, which had more than 1,000 runners registered

A special route around the Air Base

This year, due to the works that prevented the normal circuit of previous editions, the Churriana Integra Race included in one of its sections the Armilla Air Base, being able to run through an area hitherto unexplored in the event and making this year a special occasion.

A celebration of sport and inclusion

The City Council of Churriana de la Vega and the Granada Integra Foundation wanted to close the event with a solidarity paella for all participants, demonstrating that sport brings people together and motivates us to get the best out of ourselves.

Don’t miss the video of the event!

ROVI lays the foundations for its future growth: it forecasts that its contract manufacturing business sales will double by 2030.

• ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase in its contract manufacturing business sales.
• The company will reinforce its current position as one of the major global leaders in the fill and finish of injectables after expanding its installed capacity.
• ROVI expects the specialty pharmaceutical division to grow annually by a low-single-digit percentage in the period from 2024 to 2030, with Okedi® as the primary growth driver.
• The company plans to commence the next phases of the clinical development of Letrozole SIE and three-monthly risperidone.

You can watch the presentation of the Capital Markets Day ROVI 2025 in this video.

Laboratorios Farmacéuticos ROVI announces the full-year results for 2024, a key year for setting the bases for ROVI’s future, focused on increasing our production capacities in the contract manufacturing business and reinforcing the company’s internationalisation with Risperidone ISM®.

In 2024, the company obtained operating revenue of 763.7 million euros; EBITDA of 207.4 million euros; and a net profit of 136.9 million euros.

The contract manufacturing business (CDMO) decreased 18% compared to 2023, dropping to 336.2 million, as a consequence of:

– lower revenue related to the manufacture of the COVID-19 vaccine compared with 2023, when ROVI booked higher revenue related to the production of the “pandemic” COVID-19 vaccine; and – lower revenue related to the activities carried out to prepare the plant for vaccine production under the agreement with Moderna.

Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 28.8 million euros in 2024. Okedi® sales in 2024 doubled those of 2023.

Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) slightly decreased by 1% to 248.7 million euros in 2024, mainly due to lower orders from enoxaparin partners throughout the year.

In December 2024, for the fifth year running, ROVI improved its ESG risk rating awarded by Sustainalytics, achieving a low risk of 16.1, compared to 16.4 the previous year. The Company was placed fifth in the world ESG risk ranking from among the 424 companies evaluated in the pharmaceutical industry.

Financial donation of 250,000 euros for the reconstruction of damaged areas

We are pleased to announce that Laboratorios Farmacéuticos ROVI has made a donation of 250,000 euros to the solidarity account set up by the Generalitat Valenciana for the repair of damage and reconstruction of the areas affected by the DANA of 29th of October.

This contribution is part of the actions that the company carries out in emergency and humanitarian situations through the group’s Donations Committee. In this case, the funds will be used to repair the serious material damage caused in numerous urban and rural areas of the province of Valencia as a result of the intense rainfall and floods.

With this collaboration, we hope to contribute to a speedy recovery of the affected areas and the restoration of normal daily life.

Today, 25 November, is the International Day for the Elimination of Violence against Women.

At ROVI we do not tolerate harassment and we reject any form of violence, physical, sexual, psychological or moral harassment, abuse of authority at work or any other form of harassment or conduct that creates an intimidating or offensive environment for the rights of our employees.

ROVI also has an internal information system (Ethics Channel) which allows for fluid and effective communication with the bodies responsible for ensuring compliance with the company’s Code of Ethics, guaranteeing confidentiality and non-retaliation in the event of any type of harassment, abuse or violence suffered by a ROVI employee.

The City Council of Alcalá de Henares, in collaboration with the Official College of Pharmacists of Madrid (COFM), Laboratorios ROVI and the Foundation “España Salud”, have presented the project “Farmacias Cardioprotectoras”, which will allow a total of 24 pharmacies in this city, located in areas where this type of assistance is not forthcoming, to have a defibrillation equipment at the service of anyone who needs it.

This initiative provides for the installation of defibrillators in selected pharmacies, especially those with extended opening hours and away from other health centres. As health professionals closest to the population, community pharmacists will receive the necessary training to act in time, in order to reverse episodes of sudden death or sudden onset of cardiac arrest. The objective is to create a safety network of cardioprotective pharmacies to guarantee the population quick access to these devices, to reduce the number of deaths associated with cardiorespiratory arrests.

Cardiovascular problems are today the first cause of death in women and the second in men in Spain, accounting for 30% of deaths. Defibrillation has been shown to be an effective treatment that involves delivering a controlled electrical shock to the heart with the defibrillator.

“With this project, the pharmacy network once again demonstrates that it offers solutions to improve the care and health of the population; we want to offer greater peace of mind and tell citizens that we are better prepared to face an emergency, where reaction time is key to saving a life,” said the president of COFM, Manuel Martínez del Peral.

Dear colleagues,

I am writing to announce an important transformation in the management of Laboratorios Farmacéuticos ROVI’s most important asset: its employees. As part of our commitment to the continuous improvement and optimisation of our internal processes, we have decided to implement an important change in our human resource management computer system so that we can become swifter and more agile.

To this end, we are going to adopt the Workday programme, a new tool with which we will unify and simplify the people-related administrative and management tasks at ROVI.

This new platform will allow us to centralise human resource management, furnishing each employee with greater autonomy and self-management capacity. When it has been implemented, you will be able to administer aspects related to your time, salary and professional development more directly, with updated information and easily accessible tools.

Impact on the human resources team

With this new computer system, the human resources team will be freed from various administrative tasks, which will allow them to take on a more strategic role in accompanying our workforce and providing advice on their needs. This change will enable the team to focus on supporting the professional development of each colleague and promoting an inclusive and collaborative work environment.

Next step

As of 1 October, Workday will become our partner for day-to-day procedures and may be accessed from both computers and mobile phones. As you know, we have begun/conducted a round of face-to-face sessions to familiarise our employees with the programme and favour their adaptation to the new system and its functionalities.

We firmly believe that this transformation will represent a significant advance for our organisation, allowing us to improve efficiency, autonomy and collaboration at all levels. From the human resources team, we would like to thank you for your commitment and cooperation in making this project a success and we reiterate that we will continue to work with you to enable ROVI to continue growing.

We have the pleasure of announcing that the Board of Directors of Laboratorios Farmacéuticos ROVI has approved the new Human Rights Policy. In this Policy, the Group, as a member of the United Nations Global Compact, reaffirms its commitment to ensuring that the activities conducted in the course of both its own operations and those of its value chain do not violate human rates or the Fundamental Conventions of the International Labour Organisation.

Respect for human rights is one of the basic pillars of ROVI’s values, as set out in its Code of Ethics, Environmental and Social Sustainability Policy and Corporate Social Responsibility Programme, in accordance with the standard SA8000. This new policy supplements these principles with the goal of generating a positive impact on ROVI’s stakeholders (workers, patients, healthcare professionals, suppliers and society) and ensuring that all the Group’s actions are guided by the strictest ethical standards.